Abstracts tagged "gout"

Abstract Number: 1991 • 2013 ACR/ARHP Annual Meeting
Gout In Ambulatory Care Settings In The US: 1993-2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily cared for in ambulatory care settings. Yet, there are few nationally representative data on ambulatory health care utilization of…
Abstract Number: 1196 • 2013 ACR/ARHP Annual Meeting
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
Mireille Aujero¹, J. Steuart Richards², Carl A. Nunziato³, David D. Maron⁴ and Gail S. Kerr⁵, ¹Rheuamtology Section, Washington DC VA Medical Center and Georgetown University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Howard University Hospital, Washington, DC, ⁴Research Department, Washington DC VA Medical Center, Washington, DC, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: ACR 2012 management guidelines for tophaceous gout (TG) recommend urate lowering therapies (ULT) to achieve a target serum uric acid (SUA) of < 6.0…
Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 1992 • 2013 ACR/ARHP Annual Meeting
Trends In Outpatient Treatment Of Gout In The US: From 1993 To 2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily managed in the community by primary care providers. Relatively little is known about the treatment patterns as well as…
Abstract Number: 1174 • 2013 ACR/ARHP Annual Meeting
Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
Nicola Dalbeth¹, Peggy Chen², Marie White³, Gregory Gamble⁴, Caran Barratt-Boyes², Peter J. Gow⁵ and Brandon Orr-Walker², ¹Medicine, University of Auckland, Auckland, New Zealand, ²Counties Manukau District Health Board, Auckland, New Zealand, ³CCRep, Auckland, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Rheumatology Dept, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: Weight loss leads to reduced serum urate (SU) in people with obesity. However, the clinical relevance of such reductions in SU are unknown. This…
Abstract Number: 858 • 2013 ACR/ARHP Annual Meeting
Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
Eric W. Orlowsky¹, Thomas V. Stabler², Eulalia Montell³, Josep Verges³ and Virginia B. Kraus², ¹Divsion of Rheumatology, Dept of Internal Medicine, Duke University Medical Center, Durham, NC, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Pre-Clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is characterized by acute episodes of joint pain. Monosodium urate (MSU) crystals…
Abstract Number: 1989 • 2013 ACR/ARHP Annual Meeting
Determinants Of Functional Disability In Patients With Gout: Longitudinal Analysis From a Multicentre Observational Study Of The Italian Society For Rheumatology
Carlo Alberto Scirè¹, Maria Manara¹, Greta Carrara¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Leonardo Punzi⁵, Carlomaurizio Montecucco⁶, Marco Matucci-Cerinic⁷ and Giovanni Minisola⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁶Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁷Rheumatology, University of Florence, Azienda Ospedaliera Careggi, Florence, Italy, ⁸Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Italy
Background/Purpose: Gout is the most prevalent arthritis and significantly impacts on function. Beside the influence of concurrent comorbidities, identifying disease-related prognostic factors may help to…
Abstract Number: 1176 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
Anthony J. Bleyer¹, David E. Wright² and Alan Glicklich³, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Savient Pharmaceuticals, Inc., San Diego, CA, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Among the estimated 8.3 million adults in the US with gout, approximately 40% have coexistent chronic kidney disease (CKD).1,2 Further, the presence of gout…
Abstract Number: 861 • 2013 ACR/ARHP Annual Meeting
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
Max I. Hamburger¹, Michael H. Pillinger², Robert Sederman³ and Gary Fernandez⁴, ¹Rheumatology Associates, Melville, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³C1 Consulting, LLC, Summit, NJ, ⁴Market Research, Savient Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of…
Abstract Number: 1990 • 2013 ACR/ARHP Annual Meeting
Treatment Of ACUTE Gout In The Emergency Department Evaluated According To The 2012 American College Of Rheumatology Guidelines
Naomi Schlesinger¹, Tina Chang Young², Diane C. Radvanski³, Dirk Moore⁴ and Robert Eisenstein⁵, ¹Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Biostatistics, UMDNJ/School of Public Health, Piscataway, NJ, ³Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Department of Biostatistics, UMDNJ - School of Public Health, Piscataway, NJ, ⁵, Department of Emergency Medicine, UMDNJ- Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Acute gout attacks account for a substantial number of emergency department (ED) visits. Our aim was to record acute gout treatment in the ED…
Abstract Number: 1180 • 2013 ACR/ARHP Annual Meeting
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
Chang-Fu Kuo^1,2, Michael Doherty³, Matthew J. Grainge⁴ and Weiya Zhang¹, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, ⁴Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To describe the trends of epidemiology of gout and patterns of urate-lowering treatment in the UK general population from 1997-2012. Methods: We used the…
Abstract Number: 405 • 2013 ACR/ARHP Annual Meeting
Gout and RA: Not Such a Rare Coexistence After All
Christina Petsch¹, Elizabeth Araujo¹, Matthias Englbrecht¹, Axel J. Hueber², Georg Schett¹, Bernhard Manger¹ and Juergen Rech², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been…
Abstract Number: 1993 • 2013 ACR/ARHP Annual Meeting
Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Chang-Fu Kuo^1,2, Michael Doherty³, Matthew J. Grainge⁴ and Weiya Zhang¹, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, ⁴Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To examine geographic variations of gout prevalence, incidence and management in the United Kingdom. Methods: We used the Clinical Practice Research Data-link (CPRD) to…
Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Kowoon Joo¹, Won Park¹, Seong-Ryul Kwon¹, Mie-Jin Lim¹, Kyong-Hee Jung¹, Hoyeon Joo¹ and Sung-Soo Kim², ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan Univ College of Medicine and Gangneung Asan Hospital, Gangneung, South Korea
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…
Abstract Number: 212 • 2013 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Ashwin Rajan¹, Opetaia Aati², Ramanamma Kalluru³, Gregory Gamble², Anne Horne², Anthony Doyle¹, Fiona M. McQueen⁴ and Nicola Dalbeth⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Dual-energy computed tomography (DECT) is an advanced imaging method with potential for monitoring urate deposition in patients with gout. The aim of this prospective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.